Cullinan Management (CGEM)
NASDAQ:CGEM
CGEM Stock Chart & Stats
$14.86
-$0.28(-2.38%)
At close: 4:00 PM EST
$14.86
-$0.28(-2.38%)
Day’s Range― - ―
52-Week Range$5.68 - $16.74
Previous CloseN/A
Volume73.34K
Average Volume (3M)868.81K
Market Cap
$905.47M
Enterprise Value$819.82M
Total Cash (Recent Filing)$377.90M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 07, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding60,526,127
10 Day Avg. Volume843,934
30 Day Avg. Volume868,808
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.29K
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$29.98Price Target Upside101.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.02
Revenue Forecast (FY)$25.31M
Bulls Say, Bears Say
Bulls Say
Clinical Data Catalyst For Autoimmune ProgramInitial clinical data for CLN-978 in rheumatoid arthritis and systemic lupus erythematosus that demonstrate safety, tissue B‑cell depletion, and early signs of activity could validate the mechanism and attract renewed investor interest.
Intellectual Property ProtectionIssuance of a composition of matter patent for CLN-978 strengthens intellectual property protection and enhances the asset's commercial exclusivity profile.
Oncology Program AdvancementEncouraging early responses for CLN-049 in acute myeloid leukemia, combined with plans for a registrational single-arm study and frontline combination trials, could create significant value if durable remissions are confirmed.
Bears Say
Clinical Outcome UncertaintyProgress depends on dose‑escalation and clinical readouts, and unfavorable results at higher doses or on durability measures could materially reduce the company's valuation.
Dose Optimization RiskManagement's statement that a single non‑optimized dose is unlikely to produce a full immune reset indicates that multiple or optimized dosing regimens may be required, increasing development complexity and risk.
Financial And Valuation PressureNegative return on equity, weak profitability, and shares trading below the company's offering price create valuation pressure and heighten sensitivity to clinical delays or setbacks.
Cullinan Management News
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $5.68 and its highest was $16.74 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $905.47M.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is May 07, 2026 which is in 28 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Mar 10, 2026. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.809 by $0.039.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.84.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 60,526,127 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.809. Following the earnings report the stock price went down -2.613%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.98 (101.75% Upside)
$29.98 (101.75% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $772.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.34%
12-Months-Change
Fundamentals
Return on Equity
-46.19%
Trailing 12-Months
Asset Growth
-27.84%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CGEM Stock 12 Month Forecast
Average Price Target
$29.98
▲(101.75% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---